Sunvozertinib
Dizal Pharmaceuticals
['sunvozertinib', 'lcsm,(-blcsm)']
sunvozertinib egfr exon20 ins inhibitor -orr 60.8% across exon20ins subtypes -corr 48.5% in pts with cns mets
-toxicity profile w/ high rates of diarrhea, rash, anemia #asco23 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.